540,024 Shares in Establishment Labs Holdings Inc. (NASDAQ:ESTA) Purchased by Toronto Dominion Bank

Toronto Dominion Bank bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 540,024 shares of the company's stock, valued at approximately $24,879,000. Toronto Dominion Bank owned about 1.93% of Establishment Labs as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ESTA. Brown Advisory Inc. boosted its holdings in shares of Establishment Labs by 23.1% during the 4th quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock worth $107,729,000 after buying an additional 438,057 shares during the period. Capital Research Global Investors boosted its holdings in shares of Establishment Labs by 29.3% during the 4th quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock worth $88,064,000 after buying an additional 433,484 shares during the period. Findell Capital Management LLC boosted its holdings in shares of Establishment Labs by 28.5% during the 4th quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company's stock worth $62,032,000 after buying an additional 298,380 shares during the period. William Blair Investment Management LLC boosted its holdings in shares of Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock worth $37,447,000 after buying an additional 248,888 shares during the period. Finally, Bamco Inc. NY boosted its holdings in shares of Establishment Labs by 53.8% during the 4th quarter. Bamco Inc. NY now owns 752,886 shares of the company's stock worth $34,685,000 after buying an additional 263,500 shares during the period. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on ESTA. Stephens reiterated an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research note on Thursday, March 6th. Wall Street Zen cut shares of Establishment Labs from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. BTIG Research began coverage on shares of Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 target price for the company. Finally, Needham & Company LLC upgraded shares of Establishment Labs from a "hold" rating to a "buy" rating and set a $48.00 target price for the company in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.33.

Establishment Labs Price Performance

Shares of ESTA stock traded down $0.04 during mid-day trading on Friday, reaching $34.64. The company's stock had a trading volume of 445,316 shares, compared to its average volume of 476,482. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $58.00. The company has a market cap of $1.00 billion, a P/E ratio of -13.43 and a beta of 0.73. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The firm's 50-day moving average is $33.87 and its two-hundred day moving average is $37.58.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The company had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. During the same quarter in the prior year, the company posted ($0.58) EPS. The business's revenue was up 11.3% on a year-over-year basis. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.